The Idyeas Group

About The Idyeas Group

Strategic Capital Advisory for Seed–Series A Biotech, MedTech & Digital Health The Idyeas Group provides strategic capital advisory to Seed–Series A biotech and health innovation companies navigating critical funding inflection points. We work with founders and boards to align capital sequencing, milestone architecture, and investor positioning—particularly where non-dilutive federal funding and institutional venture capital intersect. Our focus is on ensuring that capital strategy holds together as an integrated system under investor scrutiny. When sequencing, milestones, and capital risk are aligned, companies move through the raise with greater clarity, credibility, and momentum. Engagements are selective and aligned with active capital formation. Also supporting board and governance roles related to capital strategy, milestone oversight, and institutional readiness. We have: • Supported founders in preparing capital strategy and investor positioning • Advised early-stage health innovation companies on integrated federal and equity funding pathways • Refined capital narratives, milestone strategy, and investor targeting